Incidence of severe COVID-19 in a Spanish cohort of 1037 patients with rheumatic diseases treated with biologics and JAK-inhibitors

V Jovani, I Calabuig, ML Peral-Garrido… - Annals of the …, 2022 - ard.bmj.com
The recent outbreak of the novel severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2), responsible for COVID-19, has brought about a great concern for the management …

[HTML][HTML] Understanding the cytokine storm during COVID-19: Contribution of preexisting chronic inflammation

P Miossec - European Journal of Rheumatology, 2020 - ncbi.nlm.nih.gov
Infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus can
lead to clinical expression of the coronavirus disease (COVID-19). COVID-19 itself has a …

The rheumatologist's role in COVID-19

RQ Cron, WW Chatham - The Journal of rheumatology, 2020 - jrheum.org
The novel coronavirus (severe acute respiratory syndrome; SARS-CoV-2) pandemic has
spread rapidly throughout the planet. It is believed to have originated in the Wuhan province …

Preliminary predictive criteria for COVID-19 cytokine storm

R Caricchio, M Gallucci, C Dass, X Zhang… - Annals of the …, 2021 - ard.bmj.com
Objectives To develop predictive criteria for COVID-19-associated cytokine storm (CS), a
severe hyperimmune response that results in organ damage in some patients infected with …

[HTML][HTML] Why judiciously timed anti-IL 6 therapy may be of benefit in severe COVID-19 infection

L Cunningham, I Kimber, DA Basketter… - Autoimmunity …, 2020 - ncbi.nlm.nih.gov
We read with interest the recent article by McGonagle et al. on the role played by interleukin-
6 (IL-6) in severe COVID-19-induced pneumonia and macrophage activation syndrome …

Sepsis-associated severe interleukin-6 storm in critical coronavirus disease 2019

L Huang, X Zhao, Y Qi, H Li, G Ye, Y Liu… - Cellular & molecular …, 2020 - nature.com
Coronavirus disease 2019 (COVID-19) is a respiratory disease caused by a novel
coronavirus known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). 1, 2 …

Association of interleukin 7 immunotherapy with lymphocyte counts among patients with severe coronavirus disease 2019 (COVID-19)

PF Laterre, B François, C Collienne… - JAMA network …, 2020 - jamanetwork.com
Cytokine storm–mediated organ injury continues to dominate current thinking as the primary
mechanism for coronavirus disease 2019 (COVID-19). Although there is an initial hyper …

Immunopathology and immunopharmacotherapy of coronavirus disease 2019 (COVID-19): focus on interleukin 6

E Nasonov - 2021 - covid19.neicon.ru
The Coronavirus Disease 2019 (COVID-19) pandemic has drawn closer attention than ever
before to the problems of the immunopathology of human diseases, many of which have …

Tocilizumab for cytokine storm syndrome in COVID-19 pneumonia: an increased risk for candidemia?

S Antinori, C Bonazzetti, G Gubertini, A Capetti… - Autoimmunity …, 2020 - ncbi.nlm.nih.gov
We have read with interest the excellent review by McGonagle et al. discussing the possible
role of hyperinflammation secondary to macrophage activation syndrome (MAS) or cytokine …

Prevention of the cytokine storm in COVID-19

DJM Wright - The Lancet Infectious Diseases, 2021 - thelancet.com
Correspondence 26 www. thelancet. com/infection Vol 21 January 2021 acceleration of
cases seen in the eastern region (99 cases per 100 000). Per 100 000 population, Mecca …